Business / Finance RSS Feed - Business / Finance

Elsevier announces acquisition of London-based InferMed

Elsevier announces acquisition of London-based InferMed

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the acquisition of InferMed, a London-based clinical decision support (CDS) technology company. [More]
Isagenix International recognized at 2015 Annual American Business Awards gala

Isagenix International recognized at 2015 Annual American Business Awards gala

Isagenix International, a leading global health and wellness company, announced it has earned three Gold, three Silver, and three Bronze Stevie Awards at the 2015 Annual American Business Awards gala held in Chicago this month. The American Business Awards are recognized as the premier business awards program in the U.S. [More]
Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea Biotechnologies Inc. announced today that it is partnering with Aelan Cell Technologies Inc. (San Francisco, California) for the development, validation and commercialization of novel biomarker tests and companion diagnostics using human STEM cells as models. [More]
Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

UCB, a multinational biopharmaceutical company, and Genpact, a global leader in designing, transforming, and running intelligent business operations, have received the Aecus Innovation Award in recognition of their close collaboration in driving transformation that achieved far-reaching operational efficiencies in UCB's global business services (GBS) finance organization. [More]
R-Japan receives license for cell processing facility

R-Japan receives license for cell processing facility

R-Japan Co.,Ltd. obtained the license of cell processing facility under the Act on the Safety of Regenerative Medicine from the Ministry of Health, Labour and Welfare Kinki Bureau of Health and Welfare on June 29, 2015. [More]
Inari Medical closes $12.4 million Series B venture capital financing

Inari Medical closes $12.4 million Series B venture capital financing

Inari Medical, Inc. announced today that it has closed a $12.4 million Series B venture capital financing. The financing was led by members of the board of directors and returning investors Versant Ventures and US Venture Partners. The round also included participation by several medical device industry veterans. [More]
EnteroMedics announces pricing of previously announced public offering of common stock

EnteroMedics announces pricing of previously announced public offering of common stock

EnteroMedics Inc., a developer and manufacturer of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, announced the pricing of its previously announced public offering of 40,229,886 units. [More]
CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, announced today that, as part of its global manufacturing capacity expansion strategy, it has completed the expansion of its North American manufacturing facility in Bothell, Washington with the addition of a single-use Bioreactor 6Packā„¢ facility. [More]
Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. [More]
Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics, Inc. announces the receipt of a Phase II SBIR grant in the amount of $1.54 million dollars from the U.S. National Institutes of Health to advance its novel Re-engineering with Metabolism Preserved (RAMP) medicinal chemistry program. [More]
Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare. [More]
Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. [More]
iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics, today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. [More]
Bristol-Myers Squibb to establish R&D center in Cambridge Kendall Square innovation cluster

Bristol-Myers Squibb to establish R&D center in Cambridge Kendall Square innovation cluster

Alexandria Real Estate Equities, Inc., the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, announced today that Bristol-Myers Squibb, a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster. [More]

ATL Technology expands global footprint with acquisition of MedConx

ATL Technology, LLC, a top provider of electromechanical contract manufacturing of assemblies and devices with specialties in single use solutions, headquartered in Springville, Utah, has announced the acquisition of MedConx, Inc. (a California corporation with locations in Santa Clara, CA, and San Jose, Costa Rica). [More]
Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX. [More]

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. [More]
Impax Laboratories prices convertible senior notes due 2022 in private offering

Impax Laboratories prices convertible senior notes due 2022 in private offering

Impax Laboratories, Inc. priced $500,000,000 aggregate principal amount of 2.00% convertible senior notes due 2022 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). [More]
Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration. [More]
The Volunteer Center honors McKesson with 2015 Corporate Community Involvement Award

The Volunteer Center honors McKesson with 2015 Corporate Community Involvement Award

As part of its annual Bay Area Volunteer Awards, The Volunteer Center has named McKesson the recipient of its 2015 Corporate Community Involvement Award. [More]
Advertisement
Advertisement